(Total Views: 497)
Posted On: 09/02/2020 3:03:38 PM
Post# of 154117
CC Agenda
Details of the current discussions with MHRA in regards to fast track approval for COVID-19
Status of Emergency Use Approval for COVID-19, CD10 trial in U.S.
Detail discussions of the cancer results and discussions from invited guest (from Creative MicroTech) on the leronlimab potential in all cancers based on current results in the last 1 year
HIV – BLA submission in U.S. and U.K.
HIV – cure project
NASH timeline
Potential other trials
Scientific Advisory Board
NASDAQ uplist
If one wanted to read anything into it, you could say he's saving significant news on the NASDAQ uplist for the end of the call. As someone reminded me a few weeks, the call with the Vyera announcement was just about the worst one ever (until the lawsuit defense), up until the end when he said we had a deal.
I'm also seeing the BLA submission after the guest and the cure project (why even talk about this now with so much current).
Details of the current discussions with MHRA in regards to fast track approval for COVID-19
Status of Emergency Use Approval for COVID-19, CD10 trial in U.S.
Detail discussions of the cancer results and discussions from invited guest (from Creative MicroTech) on the leronlimab potential in all cancers based on current results in the last 1 year
HIV – BLA submission in U.S. and U.K.
HIV – cure project
NASH timeline
Potential other trials
Scientific Advisory Board
NASDAQ uplist
If one wanted to read anything into it, you could say he's saving significant news on the NASDAQ uplist for the end of the call. As someone reminded me a few weeks, the call with the Vyera announcement was just about the worst one ever (until the lawsuit defense), up until the end when he said we had a deal.
I'm also seeing the BLA submission after the guest and the cure project (why even talk about this now with so much current).
(2)
(0)
